Skip to main content
. 2020 May 18;10:8140. doi: 10.1038/s41598-020-64629-6

Table 3.

Risk reclassification tables.

Re-estimated equation
Framingham 1991 general CVD
<1.25% 1.25 – 2.49% 2.50 – 3.74% 3.75 - 4.99% 5.00 – 7.49% 7.50 - 9.99% ≥ 10.00% Total
Original equation <1.25% 149,963 (28.5) 10,905 (2.1) 279 (0.1) 10 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 161,157 (30.7)
1.25 – 2.49% 24,297 (4.6) 43,903 (8.4) 10,101 (1.9) 1,639 (0.3) 274 (0.1) 0 (0.0) 0 (0.0) 80,214 (15.3)
2.50 – 3.74% 2,354 (0.4) 21,582 (4.1) 20,591 (3.9) 8,259 (1.6) 3,649 (0.7) 31 (0.0) 0 (0.0) 56,466 (10.7)
3.75 – 4.99% 282 (0.1) 6,271 (1.2) 14,364 (2.7) 11,976 (2.3) 10,038 (1.9) 1,001 (0.2) 11 (0.0) 43,943 (8.4)
5.00 – 7.49% 30 (0.0) 1,902 (0.4) 9,197 (1.8) 14,796 (2.8) 24,873 (4.7) 10,944 (2.1) 1,074 (0.2) 62,816 (12.0)
7.50 – 9.99% 1 (0.0) 113 (0.0) 1,260 (0.2) 4,106 (0.8) 14,310 (2.7) 13,637 (2.6) 7,201 (1.4) 40,628 (7.7)
≥10.00% 0 (0.0) 9 (0.0) 160 (0.0) 797 (0.2) 6,930 (1.3) 14,039 (2.7) 58,339 (11.1) 80,274 (15.3)
Total 176,927 (33.7) 84,685 (16.1) 55,952 (10.6) 41,583 (7.9) 60,074 (11.4) 39,652 (7.5) 66,625 (12.7) 525,498 (100)
Framingham 2008 general CVD
Original equation <1.25% 104,862 (19.7) 1,921 (0.4) 34 (0.0) 1 (0.0) 1 (0.0) 0 (0.0) 0 (0.0) 106,819 (20.1)
1.25 – 2.49% 60,326 (11.3) 36,074 (6.8) 4,059 (0.8) 743 (0.1) 221 (0.0) 19 (0.0) 0 (0.0) 101,442 (19.0)
2.50 – 3.74% 7,863 (1.5) 37,049 (7.0) 16,900 (3.2) 5,026 (0.9) 2,585 (0.5) 274 (0.1) 24 (0.0) 69,721 (13.1)
3.75 – 4.99% 812 (0.2) 13,884 (2.6) 18,638 (3.5) 9,734 (1.8) 6,998 (1.3) 1,415 (0.3) 174 (0.0) 51,655 (9.7)
5.00 – 7.49% 99 (0.0) 4,632 (0.9) 16,019 (3.0) 17,749 (3.3) 21,158 (4.0) 8,086 (1.5) 2,236 (0.4) 69,979 (13.1)
7.50 – 9.99% 4 (0.0) 263 (0.0) 2,687 (0.5) 6,564 (1.2) 15,737 (3.0) 11,089 (2.1) 6,887 (1.3) 43,231 (8.1)
≥10.00% 0 (0.0) 33 (0.0) 390 (0.1) 1,827 (0.3) 10,427 (2.0) 16,216 (3.0) 60,928 (11.4) 89,821 (16.9)
Total 173,966 (32.7) 93,856 (17.6) 58,727 (11.0) 41,644 (7.8) 57,127 (10.7) 37,099 (7.0) 70,249 (13.2) 532,668 (100)
Pooled Cohort ASCVD Equations
Original equation <1.25% 84,567 (19.0) 74,867 (16.8) 11,528 (2.6) 505 (0.1) 34 (0.0) 0 (0.0) 0 (0.0) 171,501 (38.5)
1.25 – 2.49% 13 (0.0) 11,515 (2.6) 40,907 (9.2) 20,176 (4.5) 5,614 (1.3) 185 (0.0) 14 (0.0) 78,424 (17.6)
2.50 – 3.74% 0 (0.0) 168 (0.0) 4,258 (1.0) 16,734 (3.8) 22,951 (5.2) 3,353 (0.8) 305 (0.1) 47,769 (10.7)
3.75 – 4.99% 0 (0.0) 14 (0.0) 176 (0.0) 2,754 (0.6) 18,402 (4.1) 9,925 (2.2) 2,166 (0.5) 33,437 (7.5)
5.00 – 7.49% 0 (0.0) 3 (0.0) 18 (0.0) 329 (0.1) 8,408 (1.9) 19,161 (4.3) 16,134 (3.6) 44,053 (9.9)
7.50 – 9.99% 0 (0.0) 0 (0.0) 0 (0.0) 7 (0.0) 513 (0.1) 4,127 (0.9) 22,348 (5.0) 26,995 (6.1)
≥10.00% 0 (0.0) 0 (0.0) 0 (0.0) 6 (0.0) 26 (0.0) 592 (0.1) 42,382 (9.5) 43,006 (9.7)
Total 84,580 (19.0) 86,567 (19.4) 56,887 (12.8) 40,511 (9.1) 55,948 (12.6) 37,343 (8.4) 83,349 (18.7) 445,185 (100)
Legend: Observed 5-year risk (in %) for CVD and ASCVD
<1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11 11-12 12-13 13-14 14-15 15-16 16-17 17-18

Risk reclassification tables for the estimates 5-year risk (in %) for general cardiovascular disease (CVD) for the two Framingham equations and for atherosclerotic CVD (ASCVD) for the Pooled Cohort equations. Assuming constant hazard, approximately twice the estimated 5-year risk corresponds to the 10-year risk. For more details on the appropriateness of this assumption in this context and on the conversion, see Supplementary Figure 1. Individuals classified to cells in the diagonal (cells with a black frame) remain in the same risk category, irrespective if the original or the re-estimated equation is applied. All other individuals are re-classified to another risk category. Grey colors indicate the observed 5-year risk. The darker the grey color in a cell, the higher the observed 5-year risk of the individuals classified to this cell. (The observed 5-year risk was computed only for cells with at least 100 observations and at least one event.) If a re-estimated equation improves the discrimination of (AS-)CVD events, then separately for each row of Table 3, cells left of the diagonal should be colored in a lighter shade of grey compared to the cell in the diagonal, and cells right of the diagonal should be colored in a darker shade of grey compared to the cell in the diagonal. The observed 5-year risks and 95%-confidence intervals are reported in Supplementary Table 6. For a more precise view on the movement of participants between risk categories, we report reclassifications tables separate for women and men, individuals of different age groups, and for individuals with and without diabetes and hypertension in Supplementary Figure 3 and Table 7. Abbreviations: ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease.